Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

May 31, 2015

Conditions
Neuromyelitis OpticaNeuromyelitis Optica Spectrum Disorder
Interventions
DRUG

Bevacizumab

Trial Locations (1)

21287

Johns Hopkins Hospital, Baltimore

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Guthy Jackson Charitable Foundation

OTHER

lead

Johns Hopkins University

OTHER

NCT01777412 - Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations | Biotech Hunter | Biotech Hunter